AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating
ByAinvest
Wednesday, Jul 23, 2025 7:20 am ET1min read
Leerink Partners analyst Marc Goodman maintains a Buy rating on Axsome Therapeutics (AXSM) stock, citing a promising pipeline and potential sales growth. Goodman is optimistic about the anticipated submission of the sNDA for Auvelity in Alzheimer's disease agitation and NDA submission for AXS-12 targeting cataplexy in narcolepsy. He expects seven approvals by 2028, which could boost sales, particularly with the Alzheimer's indication potentially adding over $1 billion in revenue.
Leerink Partners analyst Marc Goodman has maintained his Buy rating on Axsome Therapeutics (AXSM) stock, citing a promising pipeline and potential sales growth. Goodman's optimism is driven by the company's advanced clinical programs and the potential for substantial sales growth, particularly in the Alzheimer's disease indication.Goodman expects Axsome Therapeutics to submit the supplemental New Drug Application (sNDA) for Auvelity in Alzheimer's disease agitation by the third quarter of 2025. Additionally, the company is on track to submit the New Drug Application (NDA) for AXS-12 targeting cataplexy in narcolepsy in the second half of 2025. Goodman is encouraged by the company's expectation of achieving seven approvals by 2028, which underscores the advanced stage of many of its pipeline assets.
The potential for these developments to significantly boost sales is a key factor in Goodman's positive outlook. The Alzheimer's indication, in particular, has the potential to add over $1 billion in revenue, further supporting the Buy rating. Overall, Goodman's positive outlook is driven by the robust late-stage pipeline and the potential for substantial sales growth.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $150.00 price target.
References:
[1] https://www.tipranks.com/news/ratings/optimistic-outlook-for-axsome-therapeutics-promising-pipeline-and-potential-sales-growth-drive-buy-rating-ratings?utm_medium=referral&utm_source=edition.cnn.com
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet